Establishment of individualized dosage regimen based on pharmacodynamic model considering efficacy expression process of biological agents for rheumatoid arthritis
Project/Area Number |
21590181
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Tokyo University of Pharmacy and Life Science |
Principal Investigator |
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
Keywords | 医薬品情報・安全性学 / 投与設計 / 臨床 / 薬剤反応性 / 薬学 / 遺伝子 / リウマチ / TNFα / 薬物反応生 / モデリング |
Research Abstract |
Based on pharmacodynamic model for pharmacotherapy of rheumatoid arthritis, it was thought that the effect of infliximab appeared comparatively early, although its variation was large. In contrast, the effects of adalimumab and etanerscept appeared slowly, whereas these were stably. Regarding the individual variation, the level of TNFα by the influence of single nucleotide polymorphisms(SNPs) in TNFα gene was different. It was considered that dosage regimen of each drug for individual patient can be established with the developed model in view of the individual quantitative factor of TNFα.
|
Report
(4 results)
Research Products
(1 results)